Eldecalcitol Versus Alfacalcidol for Preventing Fractures in Osteoporotic Patients.

Trial Profile

Eldecalcitol Versus Alfacalcidol for Preventing Fractures in Osteoporotic Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Eldecalcitol (Primary) ; Alfacalcidol
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 08 Aug 2013 New source identified and integrated (ClinicalTrials.gov; NCT00144456).
    • 01 Oct 2011 Results published in the Bone.
    • 24 Jan 2011 Eldecalcitol has been approved in Japan for the treatment of osteoporosis based on results from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top